PDF(Pubmed)
Abstract：
TNX-1800 is a preclinical stage synthetic-derived live attenuated chimeric horsepox virus vaccine engineered to express the SARS-CoV-2 spike (S) gene. The objectives of this study were to assess the safety, tolerability, and immunogenicity of TNX-1800 administration in Syrian golden hamsters and New Zealand white rabbits. Animals were vaccinated at three doses via percutaneous inoculation. The data showed that the single percutaneous administration of three TNX-1800 vaccine dose levels was well tolerated in both hamsters and rabbits. At all dose levels, rabbits were more decerning regarding vaccine site reaction than hamsters. Lastly, no TNX-1800 genomes could be detected at the site of vaccination. Post-vaccination, all animals had anti-SARS-CoV-2 spike protein IgG specific antibody responses. These data demonstrate that TNX-1800 infection was limited, asymptomatic, and cleared by the end of this study, and a single dose was able to generate immune responses.
摘要：
TNX-1800是一种临床前阶段合成衍生的活减毒嵌合马痘病毒疫苗，经工程改造以表达SARS-CoV-2刺突（S）基因。这项研究的目的是评估安全性，耐受性,在叙利亚金仓鼠和新西兰白兔中施用TNX-1800的免疫原性。通过经皮接种以三个剂量接种动物。数据显示,三种TNX-1800疫苗剂量水平的单次经皮施用在仓鼠和兔中都具有良好的耐受性。在所有剂量水平下，与仓鼠相比，兔子在疫苗部位反应方面更令人沮丧。最后,在疫苗接种部位未检测到TNX-1800基因组.接种疫苗后，所有动物均有抗SARS-CoV-2刺突蛋白IgG特异性抗体应答.这些数据表明TNX-1800感染是有限的，无症状，在这项研究结束时，单剂量就能产生免疫反应。
